First line crizotinib in anaplastic lymphoma kinase (ALK) rearranged squamous cell lung cancer.

Romana Mikes; Franziska Jordan; Georg Hutarew; Michael Studnicka

doi:10.1016/j.lungcan.2015.10.013

First line crizotinib in anaplastic lymphoma kinase (ALK) rearranged squamous cell lung cancer.

Romana Mikes (Erstautor/-in), Franziska Jordan, Georg Hutarew (Co-Autor/-in), Michael Studnicka (Letztautor/-in)

Publikation: Beitrag in Fachzeitschrift › Fallbericht › Begutachtung

14 Quellenangaben (Web of Science)

Originalsprache	Englisch
Seiten (von - bis)	614-616
Fachzeitschrift	LUNG CANCER
Jahrgang	90
Ausgabenummer	3
DOIs	https://doi.org/10.1016/j.lungcan.2015.10.013
Publikationsstatus	Veröffentlicht - 2015

Zugriff auf Dokument

10.1016/j.lungcan.2015.10.013

Dieses zitieren

@article{5be0c89c364f4d0d9b39879c9ecc4c16,

title = "First line crizotinib in anaplastic lymphoma kinase (ALK) rearranged squamous cell lung cancer.",

keywords = "CARCINOMA, CHEMOTHERAPY, MUTATIONS, EML4-ALK",

author = "Romana Mikes and Franziska Jordan and Georg Hutarew and Michael Studnicka",

note = "Mikes, Jordan, Studnicka: Department of Pulmonary Medicine, University Clinic Salzburg, Muellner Hauptstrasse 48, 5020 Salzburg, Austria; Hutarew: Department of Pathology, University Clinic Salzburg, Muellner Hauptstrasse 48, 5020 Salzburg, Austria",

year = "2015",

doi = "10.1016/j.lungcan.2015.10.013",

language = "English",

volume = "90",

pages = "614--616",

journal = "LUNG CANCER ",

issn = "0169-5002",

publisher = "Elsevier ",

number = "3",

}

TY - JOUR

T1 - First line crizotinib in anaplastic lymphoma kinase (ALK) rearranged squamous cell lung cancer.

AU - Mikes, Romana

AU - Jordan, Franziska

AU - Hutarew, Georg

AU - Studnicka, Michael

N1 - Mikes, Jordan, Studnicka: Department of Pulmonary Medicine, University Clinic Salzburg, Muellner Hauptstrasse 48, 5020 Salzburg, Austria; Hutarew: Department of Pathology, University Clinic Salzburg, Muellner Hauptstrasse 48, 5020 Salzburg, Austria

PY - 2015

Y1 - 2015

KW - CARCINOMA

KW - CHEMOTHERAPY

KW - MUTATIONS

KW - EML4-ALK

U2 - 10.1016/j.lungcan.2015.10.013

DO - 10.1016/j.lungcan.2015.10.013

M3 - Case report

C2 - 26519123

SN - 0169-5002

VL - 90

SP - 614

EP - 616

JO - LUNG CANCER

JF - LUNG CANCER

IS - 3

ER -